AAAAAA

   
Results: 1-9 |
Results: 9
Clinical relevance of biologic factors in male breast cancer
Authors: Meijer-van Gelder, ME Look, MP Bolt-de Vries, J Peters, HA Klijn, JGM Foekens, JA
Citation: Me. Meijer-van Gelder et al., Clinical relevance of biologic factors in male breast cancer, BREAST CANC, 68(3), 2001, pp. 249-260
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer
Authors: Foekens, JA Peters, HA Grebenchtchikov, N Look, MP Meijer-van Gelder, ME Geurts-Moespot, A van der Kwast, TH Sweep, CGJ Klijn, JGM
Citation: Ja. Foekens et al., High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer, CANCER RES, 61(14), 2001, pp. 5407-5414
Bcar1/p130Cas protein and primary breast cancer: Prognosis and response totamoxifen treatment
Authors: van der Flier, S Brinkman, A Look, MP Kok, EM Meijer-van Gelder, ME Klijn, JGM Dorssers, LCJ Foekens, JA
Citation: S. Van Der Flier et al., Bcar1/p130Cas protein and primary breast cancer: Prognosis and response totamoxifen treatment, J NAT CANC, 92(2), 2000, pp. 120-127
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer
Authors: Berns, EMJJ Foekens, JA Vossen, R Look, MP Devilee, P Henzen-Logmans, SC van Staveren, IL van Putten, WLJ Inganas, M Meijer-van Gelder, ME Cornelisse, C Claassen, CJC Portengen, H Bakker, B Klijn, JGM
Citation: Emjj. Berns et al., Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer, CANCER RES, 60(8), 2000, pp. 2155-2162
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients
Authors: Foekens, JA Peters, HA Look, MP Portengen, H Schmitt, M Kramer, MD Brunner, N Janicke, F Meijer-van Gelder, ME Henzen-Logmans, SC van Putten, WLJ Klijn, JGM
Citation: Ja. Foekens et al., The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients, CANCER RES, 60(3), 2000, pp. 636-643
Breast-conserving therapy: Proteases as risk factors in relation to survival after local relapse
Authors: Meijer-van Gelder, ME Look, MP Bolt-de Vries, J Peters, HA Klijn, JGM Foekens, JA
Citation: Me. Meijer-van Gelder et al., Breast-conserving therapy: Proteases as risk factors in relation to survival after local relapse, J CL ONCOL, 17(5), 1999, pp. 1449-1457
Genetic alterations in ovarian borderline tumours and ovarian carcinomas
Authors: Schuyer, M Henzen-Logmans, SC van der Burg, MEL Fieret, JH Derksen, C Look, MP Meijer-van Gelder, ME Klijn, JGM Foekens, JA Berns, EMJJ
Citation: M. Schuyer et al., Genetic alterations in ovarian borderline tumours and ovarian carcinomas, EUR J OB GY, 82(2), 1999, pp. 147-150
Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer
Authors: Foekens, JA Diamandis, EP Yu, H Look, MP Meijer-van Gelder, ME van Putten, WLJ Klijn, JGM
Citation: Ja. Foekens et al., Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer, BR J CANC, 79(5-6), 1999, pp. 888-894
Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810patients
Authors: Foekens, JA Look, MP Bolt-de Vries, J Meijer-van Gelder, ME van Putten, WLJ Klijn, JGM
Citation: Ja. Foekens et al., Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810patients, BR J CANC, 79(2), 1999, pp. 300-307
Risultati: 1-9 |